New combo therapy aims to fight inoperable uterine cancer

NCT ID NCT03955978

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding an immune-boosting drug (TSR-042) to standard radiation therapy is safe and effective for people with inoperable endometrial cancer. Ten participants with early-stage disease will receive both treatments. The goal is to see if the combination can help the immune system attack the tumor more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TSR-042 (a drug that helps the immune system fight cancer)
What this could lead to: If successful, this could point toward a new treatment option for people with inoperable endometrial cancer, potentially improving tumor control without major side effects.
What could go wrong: This is a very early (Phase 1) and small (10 participants) trial focused on safety, not yet proving effectiveness. The combination may cause unexpected side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE ENDOMETRIUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE ENDOMETRIUM ENDOMETRIAL CANCER

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.